Physician profile
Steven M Sugg
NPI 1750308193
$6,719.42
in general payments reported to CMS, 2019-2025
29 companies · $1,281 in 2025
The $1,281 reported for 2025 was more than what 84% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,270 · 2020: $250 · 2021: $51.03 · 2022: $863 · 2023: $1,392 · 2024: $1,613 · 2025: $1,281.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,286.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,285.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,084.27 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $613.19 | 2022-2025 | Vraylar |
| Janssen Pharmaceuticals, INC | $607.56 | 2019-2025 | Spravato, Invega, Invega Trinza |
| Takeda Pharmaceuticals U.S.A., INC. | $606.96 | 2019-2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $601.50 | 2019-2025 | Austedo Xr, Austedo, Uzedy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $553.28 | 2023-2025 | Caplyta |
| Lundbeck LLC | $394.06 | 2019-2025 | Rexulti |
| Alkermes, INC. | $274.96 | 2019-2025 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $271.63 | 2019-2025 | Fanapt |
| Supernus Pharmaceuticals, INC. | $225.70 | 2022-2025 | Qelbree, Qelbree |
| Axsome Therapeutics, INC. | $207.55 | 2023-2025 | Auvelity |
| Bausch Health US, LLC | $187.09 | 2019-2024 | Aplenzin, Wellbutrin |
| Neurocrine Biosciences, INC. | $181.53 | 2019-2025 | Ingrezza |
| Shire North American Group INC | $139.48 | 2019 | |
| Tris Pharma INC | $90.50 | 2023-2025 | Dyanavel Xr |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $90.34 | 2019 | |
| Avanir Pharmaceuticals, INC. | $85.87 | 2019-2020 | |
| Allergan, INC. | $69.96 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $68.32 | 2019-2020 | |
| Ucb, INC. | $67.32 | 2021-2022 | |
| Indivior INC. | $55.06 | 2019-2020 | |
| Orexo US, INC. | $48.08 | 2019-2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $45.40 | 2025 | Rexulti |
| Almatica Pharma LLC | $43.07 | 2022-2024 | Loreev Xr |
| Jazz Pharmaceuticals INC. | $42.88 | 2019 | |
| Kyowa Kirin, INC. | $19.04 | 2022 | |
| Adlon Therapeutics L.P. | $18.53 | 2019 | |
| Sage Therapeutics, LLC | $14.48 | 2024 | |
| Rhodes Pharmaceuticals L.P. | $11.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Sugg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.